ACADIA Pharmaceuticals (ACAD)
(Delayed Data from NSDQ)
$15.94 USD
+0.26 (1.66%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $15.95 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth D Momentum A VGM
Price, Consensus and EPS Surprise
ACAD 15.94 +0.26(1.66%)
Will ACAD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ACAD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ACAD
Axsome (AXSM) Banks on Auvelity & Sunosi to Fuel Growth
Acadia (ACAD) Q2 Earnings Beat, Product Sales Drive Revenues
ACAD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Acadia Pharmaceuticals (ACAD) Beats Q2 Earnings and Revenue Estimates
Iovance Biotherapeutics (IOVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Other News for ACAD
3 Biotech Names To Target Now
Ryan Reynolds Announces More to Parkinson?s? Campaign
Analysts Offer Insights on Healthcare Companies: Veru (VERU) and ACADIA Pharmaceuticals (ACAD)
Biotech Alert: Searches spiking for these stocks today
Oppenheimer Reaffirms Their Hold Rating on ACADIA Pharmaceuticals (ACAD)